ArticleInfection and drug resistance2025
Phenotypic and Genetic Analysis of Antimicrobial Susceptibility in
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the antimicrobial susceptibility and identify genetic determinants of resistance in Vibrio cholerae strains maintained in the culture collection of the Masgut Aikimbayev National Scientific Center for Especially Dangerous Infections (NSCEDI, Republic of Kazakhstan). The analyzed isolates were previously obtained from various environmental and laboratory sources as part of microbiological and epidemiological surveillance conducted between 1970 and 2024. Methods: Twenty-six V. cholerae isolates representing different serogroups were analyzed using phenotypic and molecular methods. Antimicrobial susceptibility was determined by the Kirby-Bauer disk diffusion test and E-test against 59 antibacterial agents from major pharmacological classes. The presence of resistance genes to β-lactams and glycopeptides was examined using the BacResista GLA Real-Time PCR Detection Kit (DNA-Technology LLC, Moscow, Russia). Results: All V. cholerae isolates demonstrated high susceptibility to key antibiotics, including doxycycline, ciprofloxacin, tetracycline, cefotaxime, and kanamycin. Sporadic intermediate resistance was observed to nalidixic acid, trimethoprim, and streptomycin. Real-time PCR screening did not detect any β-lactamase or glycopeptide resistance genes among the isolates. Conclusion: The Vibrio cholerae strains preserved in the NSCEDI collection and isolated during 1970-2024 remain highly susceptible to first-line antibiotics and lack molecular markers of resistance. These findings confirm the continued effectiveness of current antimicrobial regimens for cholera treatment and underscore the importance of ongoing national surveillance of antimicrobial resistance to ensure preparedness and biosafety in potential outbreak situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.